Mg Sulfate Versus Dexmedetomidine on Cerebral Oxygen Saturation
NCT ID: NCT06848595
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
90 participants
INTERVENTIONAL
2025-02-23
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine Versus Magnesium Sulfate Infusion in Craniotomy
NCT07199595
Dexmedetomidine Versus Magnesium Sulfate Infusion During Spinal Anesthesia
NCT03640390
Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery
NCT00494832
Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant
NCT02819089
The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia
NCT02535273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MgSO4
loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
spine surgery
spine surgery in prone position
Magnesium sulfate
Patients will receive loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
dex.
Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
spine surgery
spine surgery in prone position
Dexmedetomidine
Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
control
Patients will receive the same volume of normal saline.
spine surgery
spine surgery in prone position
Normal Saline (0.9% NaCl)
Patients will receive the same volume of normal saline.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
spine surgery
spine surgery in prone position
Magnesium sulfate
Patients will receive loading dose of 40 mg/kg of magnesium sulfate diluted in 50 ml of 0.9% saline IVI will be given in 10 min before anesthesia induction then continuous infusion of 10 mg/kg/hour during the surgery.
Dexmedetomidine
Patients will receive loading dose of 1 mcg/kg dexmedetomidine diluted in 50 ml of saline 0.9% IVI will be given in 10 min before anesthesia induction then continuous infusion of 0.5 mcg/kg/hour during the surgery.
Normal Saline (0.9% NaCl)
Patients will receive the same volume of normal saline.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* either gender.
* American Society of Anesthesiologists (ASA) physical status I and II.
Exclusion Criteria
* History of preoperative neuromuscular disease.
* Patients with preexisting cerebral pathology (such as previous episodes of cerebral ischemia or stroke).
* History of psychiatric illness.
* History of orthostatic hypotension, myocardial infarction, uncontrolled hypertension or documented carotid stenosis.
* Coagulopathy disorder.
* Patients receiving magnesium supplementation.
* Chronic use of opioids.
* Current treatment with a β-blocker or calcium channel blocker.
21 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ibrahim Elsayed
doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed Said Elgebaly, professor
Role: STUDY_DIRECTOR
Tanta University
Shimaa Farouk Abdelkader, professor
Role: STUDY_DIRECTOR
Tanta University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36265MD317/11/24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.